Investing in Geron Corporation (GERN)  ➔  Intrinsic value

Prev. close$1.52 
ModelValueUpside
Chepakovich$0.46-70%
Graham-Dodd$0.00-100%
Graham$7.66+404%
Previous Close$1.52  
Valuation MethodValuePotential 
Chepakovich Model$0.46-70%recalculate
Graham-Dodd$0.00-100%recalculate
Graham Formula$7.66+404%recalculate

Latest news

Company description

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It holds rights to imetelstat, a telomerase inhibitor in Phase 2/3 clinical trials, which inhibits the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production. The company was founded in 1990 and is headquartered in Menlo Park, California.